Resverlogix's HDL Preclinical Data is Published in Current Opinion in Investigational Drugs

CALGARY, ALBERTA--(MARKET WIRE)--Sep 12, 2007 -- Resverlogix Corp. ("Resverlogix") (Toronto:RVX.TO - News) is pleased to announce today that a portion of the Company's key preclinical data has been published in Current Opinion in Investigational Drugs. The article titled "Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis" is an article that details the many approaches to increasing ApoA-l/HDL.

ADVERTISEMENT
Mr. Donald McCaffrey, President & CEO of Resverlogix stated, "We are pleased to have our data included in this important peer reviewed journal. The data contained in this publication is an exciting segment of the comprehensive data set that Resverlogix will submit to the US Food and Drug Agency (FDA) as part of the Company's Investigational New Drug (IND) application. A Phase I Clinical trial is expected to start as early as the fourth quarter of 2007."

About ApoA-l/HDL

ApoA-I is the key protein in high-density lipoprotein (HDL or the "good cholesterol"). Over the past 50 years clinical studies have clearly demonstrated the beneficial role of ApoA-I by showing both the reversal of arterial plaque and reduction of CVD risk. Thereby ApoA-I has secured the moniker, the cardioprotective protein.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-l. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (Toronto:RVX.TO - News). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

hdl hdl cholesterol increase hdl raise hdl cholesterol hdl ratio raise hdl high hdl low hdl hdl ldl raising hdl cholesterol hdl level hdl levels increase hdl cholesterol cholesterol hdl ratio hdl cholesterol level cholesterol hdl ldl verilog hdl hdl and ldl raising hdl ldl hdl ratio active hdl hdl dumb how to increase hdl hdl dump hdl cholestrol how to raise hdl normal hdl increasing hdl hdl c what is hdl non hdl hdl cholesterol levels niacin hdl hdl patch chol hdl low hdl cholesterol good hdl high hdl cholesterol ps2 hdl hdl designer hdl foods chol hdl ratio hdl vs ldl pfizer hdl non hdl cholesterol improve hdl lower hdl tc hdl hdl colesterol hdl and ldl cholesterol hdl ldl levels hdl cholesteral raise hdl levels total cholesterol hdl raising hdl levels hdl booster hdl good cholesterol hdl design normal hdl levels hdl diet hdl and ldl levels hdl chip design hdl 2 foods that raise hdl hdl food hdl & ldl high hdl levels concept hdl hdl test hdl drug elevated total cholesterol hdl ratio hdl blood foods high in hdl cholesterol to hdl ratio how to raise hdl cholesterol hdl ldl triglycerides raise your hdl tc hdl hdl values hdl 0.8 sources of hdl how to increase hdl cholesterol aldec active hdl increase hdl levels hdl 0.8 b hdl synthesis low triglycerides hdl hdl patched increasing hdl cholesterol hdl risk factor hdl ldl ratios ldl to hdl ratio hdl cholestorol hdl com hdl metabolism improving hdl what is hdl cholesterol x hdl lowering how to improve hdl hdl to ldl very high hdl how to raise your hdl